Activity of Platinum Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer and DNA Damage Repair Gene Alterations.

Date publication

août 2025

Journal

JCO precision oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr THIERY-VUILLEMIN Antoine

Tous les auteurs :
Aldea M, Orillard E, Bernard-Tessier A, Cerbone L, Llacer C, Koster KL, Roubaud G, De Giorgi U, Joly F, Cherifi F, Rochand A, Omlin A, Beltran H, Morales-Barrera R, Annonay M, Bianchini D, de Bono J, Castro E, Baciarello G, Gillessen S, Thiery-Vuillemin A, Fizazi K

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40773712

Résumé

Up to 30% of patients with metastatic castration-resistant prostate cancer (mCRPC) have DNA damage repair (DDR) gene alterations, mainly in . PARP inhibitors (PARPi) are standard treatments for -altered patients with mCRPC, and evidence for platinum agents is limited. This study assesses single-agent platinum therapy in patients with mCRPC with and without DDR alterations.

Mots clés

Humans, Male, Prostatic Neoplasms, Castration-Resistant, drug therapy, Aged, Retrospective Studies, Middle Aged, DNA Repair, genetics, Aged, 80 and over, Platinum, therapeutic use, DNA Damage, genetics, Antineoplastic Agents, therapeutic use, Neoplasm Metastasis

Référence

JCO Precis Oncol. 2025 08;9:e2500310